Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
Nuvation gets in before Nuvalent
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
